OLEMA PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $157.7M | $124.5M | $86.1M | $82.3M | $51.1M | $13.7M | $3.9M |
| SG&A Expense | — | $21.0M | $17.7M | $18.8M | $24.7M | $20.4M | $7.8M | $403.0K |
| Operating Income | — | $-178.7M | $-142.3M | $-105.0M | $-107.0M | $-71.5M | $-21.5M | $-4.3M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | $653.0K | — |
| Pretax Income | — | $-162.4M | $-129.5M | — | — | — | — | — |
| Income Tax Expense | — | $3.0K | $2.0K | $2.0K | $1.0K | — | — | — |
| Net Income | — | $-162.5M | $-129.5M | $-96.7M | $-104.8M | $-71.1M | $-22.1M | $-4.3M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-1.87 | $-2.20 | $-2.14 | $-2.62 | $-1.80 | $-0.57 | $-0.09 |
| EPS (Diluted) | — | $-1.87 | $-2.20 | $-2.14 | $-2.62 | $-1.80 | $-0.57 | $-0.09 |
| Shares Outstanding (Basic) | 87.2M | 87.0M | 58.7M | 45.2M | 40.0M | 39.5M | 42.1M | 46.7M |
| Shares Outstanding (Diluted) | 87.2M | 87.0M | 58.7M | 45.2M | 40.0M | 39.5M | 42.1M | 46.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |